ProMab Biotechnologies Inc

What ProMab Biotechnologies Inc does

ProMab Biotechnologies, Inc. is a privately held CRO/CDMO founded in 2001 and headquartered in Richmond, California, operating an integrated platform that spans antibody engineering, CAR-T and CAR-NK cell therapy development, and mRNA-lipid nanoparticle (mRNA-LNP) gene delivery. The company offers both catalog research products (antibodies, recombinant proteins, CAR-T/CAR-NK cells, engineered cell lines, primary cells, cell media, and ready-to-use mRNA-LNPs) priced at $250-$1,900+ per unit, and custom development services with project-based quoting — for example, a multi-phase antibody-to-CAR-T development program starts at $28,795 across five phases. Underlying technology includes 10 core CAR-T/NK engineering components (bispecific scFvs, novel costimulatory domains, iCas9 suicide switches), proprietary mRNA-LNP formulations (ionizable lipid, DSPC, cholesterol, DMG-PEG2000), and two GMP manufacturing facilities using WAVE and G-Rex bioreactors capable of producing 1x10^9+ cells for preclinical and clinical use.

The company monetizes through three revenue streams: one-time catalog product sales, professional services (custom CRO/CDMO engagements), and licensing/partnering arrangements (20+ out-licensed CAR-T in vivo models). Customer segments include pharmaceutical and biotechnology companies (primary, for CAR-T/NK and mRNA-LNP development), academic and research institutions (primary, for catalog antibodies and custom antibody generation), and infectious disease researchers (secondary, for SARS-CoV-2 reagents). GTM is direct sales-led with technical sales representatives covering catalog products, CAR-T products, and custom services globally. Scale signals include 5,000+ monoclonal antibodies generated since founding, 50+ filed patents, 500+ CAR-T projects completed, 100+ CAR-T in vivo design projects, and four Phase 2 clinical trials initiated.

ProMab claims to be the only provider offering antibody engineering, CAR-T/NK development, and mRNA-LNP delivery as an integrated service stack, enabling combination approaches such as in vivo antibody expression and tumor antigen targeting. The company has executed one disclosed acquisition (One World Lab, December 2017) and maintains peer-reviewed publications in Cancers (2021-2023) covering bispecific CAR-T, CD37 CAR-T, and mRNA-LNP antibody delivery. No public revenue or funding figures are disclosed, and ownership structure beyond founder/CEO John Wu is not detailed in the source material.

Name

ProMab Biotechnologies Inc

Legal name

ProMab Biotechnologies, Inc.

Website

https://promab.com

Company type

Private

Founded year

2001

Operating status

Operating

Headcount range

101–250 employees

Short description

ProMab Biotechnologies is a private CRO/CDMO offering an integrated platform of antibody engineering, CAR-T/NK cell therapy, and mRNA-LNP gene delivery products and custom services to pharmaceutical, biotechnology, and academic researchers.

Ownership category

akta.pro rank

Product category

Contract Biopharmaceutical Research and Development Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Services-Commercial Physical & Biological Research (8731), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)

akta.pro secondary industries

Cell Therapy Developers (Allogeneic/Off-the-shelf) (HLAAABAB), Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries) (HLAAAIAL), In Vivo Discovery & Translational Models Platforms (humanized models, PK/PD, efficacy) (HLAAAIAK), Monoclonal Antibody (mAb) Biosimilars (HLAAAHAA)

Keywords

• Monoclonal antibody production
• CAR-T cell development
• MRNA lipid nanoparticles
• Custom antibody engineering
• Biopharmaceutical CRO services

Headquarters

HQ city

Richmond

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Research Products: Sale of catalog research products including antibodies, proteins, CAR-T cells, mRNA-LNPs, engineered cell lines, and cell culture reagents. Products are sold at fixed catalog prices ranging from $250 to $1900+ per item.
2. Custom Development Services (CRO/CDMO): Custom CAR-T/NK cell development, antibody engineering services, protein expression, cell-based assays, and animal studies. Services are quoted based on project scope with tiered plans (Plan A from $6,995 to $28,795 for antibody-to-CAR-T development).
3. Licensing and Partnering: Licensing of CAR technology and partnering arrangements for preclinical and clinical development. Company has 20+ out-licensed CAR-T in vivo models and offers licensing and partnering options.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels7 records

Core offering

ProMab Biotechnologies develops and sells catalog research products (antibodies, recombinant proteins, CAR-T/NK cells, primary cells, engineered cell lines, and mRNA-lipid nanoparticles) and provides custom CRO/CDMO development services spanning antibody engineering, CAR-T/NK cell therapy design and manufacturing, mRNA-LNP gene delivery, cell-based assays, protein expression, and preclinical animal studies for pharmaceutical, biotech, and academic research customers.

Product overview

ProMab Biotechnologies Inc is a biotechnology company founded in 2001 offering a comprehensive portfolio of products and services for cancer immunotherapy and antibody research. The company provides a unified platform combining three core technology areas: CAR-T/NK cell products and development services, mRNA-lipid nanoparticle (LNP) products and gene delivery services, and custom antibody engineering and production services. Product offerings include research antibodies (primary, biosimilars), recombinant and natural proteins, CAR-T and CAR-NK cells, engineered cell lines, primary cells, cell media, and mRNA-LNPs for various applications including CAR delivery, antibody expression, cell markers, and secreted proteins. Services span from discovery research through clinical development, including custom CAR design, lentivirus production, mRNA electroporation, antibody generation (mouse, rabbit, human monoclonal), cell-based assays, protein expression, and animal studies supporting preclinical and Phase 2 clinical trials.

Differentiator

Problem solved

Functional benefit

Products and services

• Antibodies Research antibody catalog including primary antibodies, biosimilars, mouse and rabbit monoclonal antibodies, and polyclonal antibodies for ELISA, FCM, ICC, IF, IHC, IP, and WB applications.
• Proteins Recombinant and natural proteins for research including cytokines, CAR-related proteins, SARS-CoV-2 proteins, and full-length proteins with reactivity across human, mouse, rat, bovine, canine, and chicken species.
• CAR-T Cells Catalog activated human T cells expressing chimeric antigen receptors targeting CD19, BCMA, HER2, EGFR, Mesothelin, and other antigens, with CD28 and 4-1BB costimulatory domains.
• CAR-NK Cells Chimeric antigen receptor natural killer cells generated from healthy donors using irradiated feeder cells, available on contract basis with expansion capacity over 1000-fold in 3-4 weeks.
• Primary Cells T cell subsets, peripheral blood monocytes, monocyte-derived macrophages, dendritic cells, and B-ALL patient PBMC isolated from healthy donors with guaranteed purity specifications.
• Engineered Cell Lines Target cell lines including overexpression lines (>90% antigen-positive guaranteed), clonal genetic knockout lines, and eGFP/luciferase marker cell lines for CAR-T/NK testing.
• Cell Media and Reagents CAR-T cell expansion media with human or fetal bovine serum, iPSC reprogramming kits, viral transduction enhancers, and freezing media for cell therapy workflows.
• mRNA-Lipid Nanoparticles Ready-to-use mRNA lipid nanoparticles for CAR delivery, antibody expression, cell markers, secreted proteins, cellular proteins, and COVID-19 variant spike proteins (Alpha, Delta, Omicron).
• SARS-CoV-2 Research Products COVID-19 research reagents including nucleocapsid protein, spike protein, RBD domain, ACE2 receptor proteins, and SARS-CoV-2 IgG detection ELISA kits.
• Custom CAR-T Cell Development Services CRO/CDMO services covering CAR design, lentivirus production, mRNA electroporation, lipid nanoparticle transfection, expansion, and validation through Phase 2 clinical trials; Plan A priced from $28,795 across five phases.
• Custom CAR-NK Cell Development Services CAR-NK manufacturing platform with antibody screening, hybridoma sequencing, mRNA transfection, lentivirus production, and CAR-NK cell expansion services; includes 20+ out-licensed CAR-T in vivo models.
• Custom Antibody Engineering Services Antibody generation services including mouse monoclonal, rabbit monoclonal, human monoclonal, recombinant antibodies, bispecific antibodies, affinity tune-up, humanization, and hybridoma sequencing.
• Cell-Based Assay Services Assay services including flow cytometry, T cell specificity, T cell activation and proliferation, cytokine response, macrophage polarization, and DC migration assays.
• Protein Expression Services Recombinant protein production in E. coli, baculovirus, and mammalian expression systems, plus stable cell line development, peptide synthesis, and gene synthesis services.
• mRNA-LNP Gene Delivery Services Custom mRNA-LNP development for vaccines, engineered immune cells, and antibody-encoding mRNA solutions using validated lipid nanoparticle formulations.
• Animal Studies In vivo preclinical studies including xenograft models for CAR-T/NK validation and efficacy assessment.

Quantifiable outcome

• CAR-T cells expanded >70% with CD28-CD3 MacroBeads transduction efficiency
• +3 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Scale indicators9 records

Recent moves6 records

Expansion highlights5 records

Market position

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/ProMabBiotech
• Facebookfacebook.com/ProMab-Biotechnologies-106932814027773
• LinkedInlinkedin.com/company/promab-biotechnologies-inc.

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ProMab Biotechnologies Inc